A USA-based firm is investing from its most recent fund, which closed in early 2020. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.
The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.
The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Panels during RESI Partnering Week, September 13 -17, are filling up with insightful investors and exceptional entrepreneurs! This 5-day partnering week consists of three different conferences, each featuring a series of exciting panels with different focuses within life sciences and healthcare.
1. Digital RESI September focuses on early-stage investment and the funding process across major sectors of healthcare and life sciences. Panelists from different investment groups are invited to provide tactical advice on outreach, positioning, and building the right relationships to move products forward.
2. RESI AI specifically targets Artificial Intelligence (AI) applications in life sciences; investors are joined by CEOs of their portfolio companies to share perspectives on current technologies and founder-investor relationships.
3. RESI Longevity co-organized with Mary Furlong & Associates, concentrates on the start-up ecosystem, market overview and regulatory landscape of the age-tech and the longevity market.
With these timely topics, we look forward to dynamic conversations and are pleased to host these industry experts at RESI Partnering Week. Check out the preliminary panelist lineup below. If you would like to meet these panelists and be part of the discussion, register now for RESI Partnering Week and save $50 when you sign up by August 6.
Featured RESI Partnering Week Panelists
Espen Agdestein Partner Idekapital AS
Paul Barbeau CTO Noetic Fund
Kareem Barghouti Co-Founder & CEO VastBiome
Jeff Chang Co-Founder & CPO Rad AI
Alicia Chong Rodriguez Founder & CEO BloomerTech
Marina Cortes Venture Partner Hike Ventures LLC
Colette Courtion CEO Joylux
Payal Divakaran Principal .406 Ventures
Karen Dolva Co-Founder & CEO No Isolation
Robert Garber Partner 7wire Ventures
Amit Garg Managing Partner Tau Ventures
Gary Gershony Partner BayMed Venture Partners
Lana Ghanem Managing Director Hikma Ventures
Jay Goss General Partner Wavemaker Three-Sixty Health
Richard Hanbury Founder & CEO Sana Health
Tai Harada Vice President Fast Track Initiative
Ozan Isinak President, Central Canada Keiretsu Forum
George Li Managing Partner Proxima Ventures
Neel Madhukar Founder OneThree Biotech
Saar Mahna Founder & CEO Banjo Health
Natalia Novac Director, Emerging Technology & Innovation Eli Lilly & Co
Michelle Perugini CEO Presagen
Stephen Pitt, PhD Head, JLABS US North East Johnson & Johnson Innovation
Garrett Rhyasen Executive Director, Global Head of Oncology Search & Evaluation, Business Development & Licensing AstraZeneca
By Rory McCann, Marketing Manager & Conference Producer, LSN
Pepper Landson has been driven by curiosity and molded by a problem-solving worldview for many years, from childhood to starting her career in HIV/AIDS research. The drive she’s developed has led her into early success with Praetego, a preclinical biotech using novel small molecule technology to address diabetic complications.
Pepper was a winner in the Digital RESI June Innovator’s Pitch Challenge, and we connected to tell more of the Praetego story and learn from her experience.
Are you interested in joining the next Innovator’s Pitch Challenge? Join RESI Partnering Week, September 13-17 and apply for a chance to pitch to a panel of active investors who are relevant for your product and stage of development. Sign up by August 6 to save!
A large pharmaceutical company headquartered in the US seeks to in-license assets and form partnerships with early-stage companies. For those fields, the firm is interested in first-in-class technology approaches and will invest in early companies with great science, from seed to series A. With their expansion to the US, the firm is now open to investing globally. The firm has generally led investments, but is willing to be part of a syndicate as well. The firm’s investments range based on the stage of the company, but will generally be no more than $5M for seed stage and no more than $10M for series A rounds.
Within therapeutics, the firm is open to both subsector and indication as long as the science is breakthrough. The firm is willing to invest earlier in platform technology companies, and will consider such technologies as early as POC stage. For companies with single assets in development, the firm prefers to see at least small animal data. For molecular diagnostics and digital health companies, the firm is opportunistic as well.
Because the firm invests early in companies with breakthrough science, they are willing to help their portfolio companies develop their strategies and operations. With its broad and trustful network with pharma companies, The firm helps portfolio companies’ boost their businesses development activities. The firm will take a board seat after investment if needed to help the company.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
The fund is the venture capital arm of a US-based company, a global supplier of building materials as well as a manufacturer of innovative material solutions. The firm is looking for companies that will align with the company strategy for either equity investments, partnerships, licensing or acquisition. Within the life sciences, the firm will consider medical devices, novel materials, diagnostics, instruments and tools. The firm is willing to invest globally, and will invest as early as prototype/proof-of-concept stage.
Within the life sciences, the firm is interested in medical device, diagnostic or instrument and tool companies. The firm will consider all medical devices, but, if FDA approval is required, the fund prefers the company to be in the approval process. For diagnostics, the fund will consider both diagnostic/monitoring machines, tools, instruments & novel materials for Genomics & Cell & Gene therapies. The firm is also interested in instruments or tools that can be used in the medical field or for research purposes.
The firm can lead or co-invest in equity investing, and their involvement in the company after investment will depend on the partnership.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
A large pharmaceutical company headquartered in the US seeks to in-license assets and form partnerships with early-stage companies. The company’s investments and partnerships are varied in size, stage and structure. In addition to capital, early-stage partners may benefit from access to the company’s expertise and research capabilities. The firm will consider opportunities worldwide.
The company invests & partners diversely in therapeutic assets, including in Oncology, Neuroscience, Diabetes and Diabetes-Related Complications, Immunology, and Drug Delivery and Devices, in addition to discovery and research tools. Generally the firm has less interest in infectious diseases, ophthalmology, and rare diseases. The company focuses on assets that represent new biological modalities. The firm will also consider device investments on occasion. The firm will consider partnerships at any stage.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Founded in 2013 and based in MA, a medical technology venture firm makes equity investments in early-stage companies developing diagnostic technologies to accelerate the trend of precision medicine. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.
The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.
The firm is looking for experienced management teams with deep domain expertise. The firm typically requests board representation post-investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Next Phase Newsletter 